Dr. Lal Path Labs Ltd. — Board Meeting, 25-04-2025: Outcome of Board Meeting

The Board of Directors approved the audited financial results for the quarter and financial year ended March 31, 2025. Revenue from operations stood at ₹24,614 crore, with a net profit of ₹4,922 crore, reflecting significant growth. A final dividend of ₹6 per equity share was proposed, pending shareholder approval, while reappointments of two independent directors were confirmed. Additionally, Ernst & Young was reappointed as internal auditors for FY 2025-26. The 31st Annual General Meeting is set for June 28, 2025.